Was Rec'd PCT/PTO 20 APR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF U.S. DEPARTME

1

### ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES 176/61692 DESIGNATED/ELECTED OFFICE (DO/EO/US) see 37 CFR 1.5) **CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PCT/US2004/035064 22 October 2003 (22.10.2003) 22 October 2004 (22.10.2004) TITLE OF INVENTION ANTI-THYMOCYTE ANTISERUM AND USE THEREOF TO TRIGGER B CELL APOPTOSIS APPLICANT(S) FOR DO/EO/US ZAND, Martin S.; IFTHIKHARUDDIN, Jainulabdeen J.; LIESVELD, Jane Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. $\overline{X}$ This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A preliminary amendment. An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19 L A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# IAP20 Rec'd PCTIPTO 20 APR 2006

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.	J.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/576428 PCT/US2004/035064		176/61692		
20. Other items or information: UNSIGNED Combined Declaration	n and Power of Attorne	у		
The following fees have been submitted			CALCULATIONS	PTO USE ONLY
21. X Basic national fee (37 CFR 1.492(a)).		\$300	\$ 300.00	
22. X Examination fee (37 CFR 1.492(c))				
If the written opinion prepared by ISAUS or the in by IPEAUS indicates all claims satisfy pro All other situations	\$ 200.00			
23. X Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0  Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority			\$ 100.00	
TOTAL OF 21, 22 and 23 =			600.00	
Additional fee for specification and drawings fled in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.  Total Sheets Extra Sheets Number of each additional 50 or fraction RATE				
46 - 100 = -54 /50 =	thereof (round up to a whole number)		\$ 0.00	
Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or dedaration after the date of commencement of the national stage (37 CFR 1.492(h)).			\$ 130.00	
CLAIMS NUMBER FILED	NUMBER EXTRA	RATE	\$	
`Total claims 56 - 20 =	36	x \$ 50	\$ 1,800.00	
Independent claims 7 - 3 =	4	× \$200	\$ 800.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360			\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =			\$ 3,330.00	
Applicant daims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.			1,665.00	
SUBTOTAL =			\$ 1,665.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$	0.00
TOTAL NATIONAL FEE =			\$	1,665.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$	0.00
TOTAL FEES ENCLOSED =			\$	1,665.00
			Amount to be refunded:	\$
			Amount to be charged	\$

10/576428

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

b. Please charge my Deposit Account No in the A duplicate copy of this sheet is enclosed.	e amount of \$ to cover the above fees.  i onal fees which may be required, or credit any overpayment to Deposit end osed.
be included on this form. Provide credit card information a	not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed
SEND ALL CORRESPONDENCE TO: Edwin V. Merkel Nixon Peabody LLP Clinton Square P. O. Box 31051 Rochester, NY 14603-1051 United States of America	SIGNATURE  Edwin V. Merkel  NAME  40,087  REGISTRATION NUMBER
·	

### 10/576428

## AP20 Rec'd PCT/PTO 20 APR 2006

#### EXPRESS MAIL CERTIFICATE

DOCKET NO.: 176/61692

APPLICANT(S): ZAND et al.

TITLE: ANTI-THYMOCYTE ANTISERUM AND USE THEREOF TO TRIGGER B CELL

APOPTOSIS

Certificate is attached to the Transmittal Letter to the U.S. Designated/Elected Office (DO/EO/US) of the above-named application.

"EXPRESS MAIL" NUMBER: EV685739184US

DATE OF DEPOSIT: April 20, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett
(Typed or printed name of person

mailing paper or fee)

(Signature of person mailing

paper or fee)